Newswise — New Haven, Conn. — Antonio Omuro, M.D., has been appointed the new Chief of Neuro-Oncology and a Leader for the Brain Tumor Program at Yale Cancer Center (YCC) and Smilow Cancer Hospital. Omuro starts his new position effective December 1, 2018.
Omuro is a graduate of the Neuro-Oncology Fellowship program at Memorial Sloan Kettering Cancer Center in New York, where he held several positions as a faculty member and researcher. He joins YCC after his most recent position as Chief of the Neuro-Oncology Division and head of the Brain Tumor program at the University of Miami. Dr. Omuro is an international leader in the clinical care and research of brain tumors, having led pivotal research programs to advance the treatment of these difficult cancers.
“I’m really excited to join Yale Cancer Center and Smilow Cancer Hospital,” Omuro said. “I know I am joining a great team, there is so much talent around! I am eager to work with our great scientists and clinicians to develop better treatments for brain tumors and together make a difference in the lives of our patients.”
Omuro is a graduate of the University of Sao Paulo School of Medicine in Brazil, his native country, where he also completed his residency in Neurology. He has also worked as a clinician and researcher at Pitie-Salpetriere Hospital, Sorbonne Universities in Paris, France.
“We are so fortunate to have recruited Dr. Omuro to lead our efforts in Brain Tumors and other nervous system cancers at our Center,” said Charles S. Fuchs, M.D., M.P.H., director of YCC. “Yale Cancer Center and Smilow Cancer Hospital are committed to meaningfully improve the outcome of patients with these cancers. Dr. Omuro will do great things at Yale and Smilow, and he will be transformational for our Neuro-Oncology program.”
About Yale Cancer Center Yale Cancer Center (YCC) is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
# # #
Available for logged-in reporters only